Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: 2006 + web + 0.28  Related to the article below (Last Update: 8/4/2008)

Web.com Reports Second Quarter 2008 Financial Results
istockAnalyst.com, OR -
Prior to the adoption of SFAS 123(R) in fiscal 2006, the Company did not include expenses related to employee stock options and employee stock purchases ...
Online Resources Posts Second Quarter 2008 Results
WELT ONLINE, Germany - Jul 29, 2008
Online Resources Corporation (Nasdaq:ORCC), a leading provider of web-based financial services, today reported financial and operating results for the three ...ORCC
Highwoods Properties Reports Second Quarter 2008 Results
Trading Markets (press release), CA - Jul 29, 2008
A live listen-only Web cast can be accessed through the Company's web site at www.highwoods.com under the "Investor Relations" section. ...HIW
Omniture Reports Second Quarter 2008 Financial Results
MarketWatch - Jul 23, 2008
The webcast will be available on the "Investor Relations" section of the company's corporate web site at www.omtr.com. A replay of the conference call will ...OMTR
UMC Reports 2008 Second Quarter Results
FOXBusiness - Jul 30, 2008
Income (Expenses) 120 71 69.0 4182 (97.1) Net Income 2397 206 1063.6 4911 (51.2) EPS (NT$ per share) 0.19 0.02 -- 0.28 -- (US$ per ADS) 0.032 0.003 -- 0.046 ...UMC
TransAlta announces strong second quarter results; on-track to ...
Earthtimes (press release), UK - Jul 31, 2008
Cash flow year-to-date was lower than the previous year due to higher contractually scheduled PPA revenues from 2006 being carried into the first quarter of ...TAC
More internet users, but basic resources remain weak: local expert
Macau Daily Times, Macau - Jul 31, 2008
... the local penetration rate of internet reached 64 percent in which the "digital divide index" continued on the fall from 0.32 in 2006 to 0.28 in 2007. ...
Are Dividends the Cure for Your Ailing Portfolio?
Morningstar.com, IL - Jul 29, 2008
Vanguard also offers an exchange-traded fund, Vanguard Dividend Appreciation , that's even cheaper, at 0.28%. It tracks the Mergent Dividend Achievers ...
Prophecy drills 45.5 metres of 0.33% copper and 0.003% Molybdenum ...
Canada NewsWire (press release), Canada - Jul 28, 2008
At Okeover, the objectives of the recent program were achieved and expanded the mineralized area of the North Lake Zone (calculated in 2006 by NC Carter, ...CVE:PCY - TSE:X - CVE:ETF
/CORRECTION from Source -- SEAMARK Asset Management Ltd./
Canada NewsWire (press release), Canada - Jul 30, 2008
The call will be web-cast live by CNW Group and available for replay for thirty days. A link to the call is available from the shareholder information ...TSE:SM
Source: Google News

Wikipedias: Collaborative web-based encyclopedias as complex networks -
V Zlatic, M Bo?icevic, H ?tefancic, M Domazet - Physical Review E, 2006 - APS
... 016115-4 WIKIPEDIAS: COLLABORATIVE WEB-BASED? PHYSICAL REVIEW E 74, 016115 2006
TABLE II. ... 6.00 5.69 7.65 13.60 10.83 9.22 All WCC 1.10 0.28 0.49 0.37 ...

[PDF] Names and similarities on the web: Fact extraction in the fast lane -
M Pasca, D Lin, J Bigham, A Lifchits, A Jain - Procs. of ACL/COLING, 2006 - acl.ldc.upenn.edu
... c 2006 Association for Computational Linguistics ... Jethro Tull: Motley Crue 0.28, Black
Crowes ... the first place, the method is impractical on Web-scale collections ...
-

Web Release Date: January 19, 2006
SN Crane, WC Black, JT Palmer, DE Davis, E Setti, … - J. Med. Chem, 2006 - pubs.acs.org
... 10.1021/jm051059p S0022-2623(05)01059-9 Web Release Date: January 19 ... Copyright ?
2006 American Chemical Society ... such as (-)-34a (hrab Cat K IC 50 0.28 nM; >800 ...

Implementation of an International Web-Based PSI Course: A Case Study -
Y Morita, J Kenne, A Nishihara, M Nakayama, BV … - Frontiers in Education Conference, 36th Annual, 2006 - doi.ieeecomputersociety.org
... 2.0 0.22 Programming classes such as this course should be Web-based. 2.6 0.27 ... 2.5
0.28 Learning Mode ... Page 5. Session S2J 1-4244-0257-3/06/$20.00 ? 2006 IEEE ...
-

… -Controlled Syntheses of In 0.08 Eu 4 (NCN) 3 I 3, Eu 8 I 9 (CN)(NCN) 3, and In 0.28 Eu 12 (NCN) 5 I … -
W Liao, R Dronskowski - Inorganic Chemistry, 2006 - pubs.acs.org
... 10.1021/ic051899u S0020-1669(05)01899-9 Web Release Date: April 8, 2006. Copyright ?
2006 American Chemical Society ... Eu 8 I 9 (CN)(NCN) 3 , and In 0.28 Eu 12 ...

[PDF] Busier Than Ever: Rethinking Reference Statistics For The Digital Age -
JM Welch - 2007 - smartech.gatech.edu
... 717: 4.76%: 26/Jan/06 21:30: /library/reference_databases/title.html 648: 0.28%:
26/Jan/06 21:21: /library/web_resources/ ... (2006). Web Server Statistics for ...
-

Which factors explain the web impact of scientists? personal homepages -
F Barjak, X Li, M Thelwall - Journal of the American Society for Information Science and …, 2007 - doi.wiley.com
... lates with the extent of collaborative research (Barjak, 2006; Cohen, 1996; Walsh
et al., 2000).As some Internet tools such as e-mail, Web sites with ...

… for Pediatric Gastroenterology, Hepatology, and Nutrition Annual Meeting, October 19-22, 2006, …
M Feist, J Fitzgerald, J Rushton, J Croffie, S … - Journal of Pediatric Gastroenterology & Nutrition, 2006 - jpgn.org
... 4, October 2006 ... significant change was seen in Chemokine receptor-2 gene (CCR-2),
which increased 7.5 folds with neutrophil migration (0.14 T 0.28 versus 1.08 ...

Heuristics for QoS-aware Web Service Composition -
R Berbner, M Spahn, N Repp, O Heckmann, R … - Proc. of the 4th Intl. Conf. on Web Services, 2006 - doi.ieeecomputersociety.org
... Second, we use a backtracking algorithm to create IEEE International Conference
on Web Services (ICWS'06) 0-7695-2669-1/06 $20.00 ? 2006 Page 2. ...

Using symbolic objects to cluster web documents -
E Meneses, O Rodr?guez-Rojas - … of the 15th international conference on World Wide Web, 2006 - portal.acm.org
... the author/owner(s). WWW 2006, May 23?26, 2006, Edinburgh, Scotland ... Histogram-10
0.7401 0.1571 0.28 s ... 3. RESULTS We used a subset of the web collection from [3 ...

Source: Google Scholar
 
 

Novel Oral Platelet Growth Factor, Eltrombopag, To Be Evaluated In Long-term Idiopathic Thrombocytopenic Purpura (ITP) Study

Article Date: 09 Dec 2006 - 6:00am (PST)
GlaxoSmithKline plc has announced the initiation of the first global randomized, double-blind and placebo-controlled Phase III trial that will assess the safety of using eltrombopag for up to six months in chronic idiopathic thrombocytopenic purpura patients. The trial, called RAISE (RAndomised placebo controlled ITP Study with Eltrombopag), will involve 189 patients who will be enrolled at 135 centers in 26 countries. Eltrombopag is an investigational agent that is not approved for use in any market for any indication at this time.

The initiation of this trial follows on from promising results seen in earlier trials. In one six week study, at eltrombopag doses of 50mg and 75mg, 70% and 81% of patients respectively achieved the primary clinical endpoint of having a platelet count greater than 50,000/ mL compared to 11% of patients on placebo.(1) In that study 47% and 61% of patients experienced at least one adverse event (AE) during treatment with eltrombopag at doses of 50mg and 75mg compared to 59% of patients receiving placebo.(1) The most common AE observed during the study was mild to moderate headache, reported in 21% subjects on placebo, 10% on eltrombopag 50mg, and 21% on eltrombopag 75mg.(1) There was no apparent relationship between dose and incidence of AE's observed in this study.

Article continues below and (thank you)
 
"We are extremely encouraged by the results from earlier eltrombopag trials", said Paolo Paoletti, MD, Senior Vice President, Oncology Medicine Development Centre, GSK. "As we continue development in Phase III trials we are very optimistic about eltrombopag in a variety of conditions where thrombocytopenia is a complicating factor. The results of this trial will represent a significant milestone for GSK and underscore our continued commitment to delivering novel treatments to potentially meet a significant unmet medical need."

Idiopathic thrombocytopenic purpura is an autoimmune disorder that is marked by increased platelet destruction and/or inadequate platelet production. This imbalance between platelet production and destruction can result in unusually low platelet counts(1) leaving patients at risk of spontaneous bruising, mucosal bleeding, and in severe cases, gastrointestinal (GI) bleeds and intracranial hemorrhage. Normal platelet counts are in the range of ≥150,000/uL and ≤400,000/uL.(2)

Current ITP treatments work to decrease platelet destruction by suppressing the patient's immune system, which can lead to increased risk of infections.(3) Eltrombopag appears to work through an entirely different mechanism - increasing platelet counts by boosting platelet production.

Eltrombopag is an investigational non-peptide small molecule that is administered orally. It is believed to function by interacting with the thrombopoietin (TPO) receptor, which is located on the surface of specific cells in the bone marrow called megakaryocytes. Megakaryocyte stimulation leads to the production of platelets, thus increasing platelet counts.

"It is exciting news that a new drug is in development which could offer chronic ITP sufferers a longer term treatment option," says Joan Young, President of the Platelet Disorder Support Association. "Current treatment options such as steroids have drawbacks if used on a long-term basis, and the more radical option of removing the spleen comes with a lifelong increased risk of severe infection. Eltrombopag may offer real hope to patients who are in need of new therapies."

Study Design

The RAISE trial will be conducted at approximately 135 investigative sites globally and 189 adults with chronic ITP will be enrolled. Eligible patients must have received one or more prior ITP therapies. The study is designed to assess the safety, efficacy and tolerability of eltrombopag for up to six months in previously treated patients with chronic ITP.

The primary outcome in the study is subjects with platelet counts between ≥50,000/uL and ≤400,000/uL during the six month treatment period. Secondary outcomes also duration of platelet count between 50,000/uL and ≤ 400,000/uL, incidence and severity of bleeding, as well as the frequency of adverse events.

About eltrombopag

Eltrombopag is an investigational thrombopoietin receptor agonist that has been shown in pre-clinical research and early phase clinical trials to stimulate the proliferation and differentiation of specific bone marrow cells that give rise to blood platelets. Therefore, eltrombopag is considered a platelet growth factor. Eltrombopag is administered orally as a tablet and may have less potential than large protein molecules for causing an immune system reaction. Eltrombopag was discovered via a research collaboration between GlaxoSmithKline and Ligand Pharmaceuticals. It is being developed solely by GlaxoSmithKline.

About thrombocytopenia and ITP

A normal blood platelet count is ≥150,000/uL and ≤400,000/uL.(2) A reduction in platelet count (to a level <150,000/mL) is the defining characteristic of thrombocytopenia and the diagnosis can be confirmed following a routine blood test. Thrombocytopenia occurs in 5% to 10% of all patients hospitalized for any cause. (4)

ITP is an autoimmune disorder that is marked by platelet destruction and/or inadequate platelet production. Primary ITP is estimated to affect 50 to 100 new persons per million per year in the United States and Europe.(5) Some patients with ITP are asymptomatic or have mild bruising while others develop mucosal bleeding that can become severe,(6) including intracranial hemorrhage.(3)

Thrombocytopenia can occur as a consequence of chemotherapy treatment, interferon treatment, viral infection or chronic liver disease. Thrombocytopenia can impede a variety of medical treatments. It can prevent cancer patients from receiving their full dose of chemotherapy, preclude patients with hepatitis C infection from receiving interferon therapy or lead to dose reductions or discontinuation, and complicate surgical or dental procedures.

###

About GlaxoSmithKline

GlaxoSmithKline is one of the world's leading research-based pharmaceutical and healthcare companies. GlaxoSmithKline is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

For company information visit http://www.gsk.com.

For further information on the trial please visit http://www.itpstudy.com or http://www.clinicaltrials.gov.

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company, including those made in this Announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the Group's operations are described under 'Risk Factors' in the 'Operating and Financial Review and Prospects' in the company's Annual Report 2005.

To access the latest GSK Oncology media materials, visit http://www.gskcancermedia.com

References:

1. Newland, A, Cheng, G, et al. Eltrombopag increases platelets during 6-week treatment of ITP - results of a randomized, double-blind, placebo-controlled phase II study. Presented 18 June, 11:00-11:15 CET

2. http://www.nlm.nih.gov/medlineplus/ency/article/003647.htm Accessed Oct 19 2006.

3. George, JN, Woolf, SH, Raskob, GE., et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996,88:3-40.

4. Mocharnuk R. Growth factors in granulocytopenia and thrombocytopenia. Presented at: 44th Annual Meeting of the American Society of Hematology; December 6-10, 2002; Philadelphia, Pa

5. Cines DB, McMillan R. Management of adult idiopathic thrombocytopenic purpura. Annu Rev Med. 2005;56:425-442.

6. Stasi, R, Provan, D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc. 2004;79:504-522.

For further information please go to:
GlaxoSmithKline
 
 
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With:News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 
 © 2002-2006

Keywords::

Contact Iconocast

Home Page